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1. Introduction  
The concept of gene therapy is defined as a biomedical technology to treat diseases with 
functional genes or therapeutic genes by transferring these genes into cells. According to the 
most comprehensive source of information on worldwide gene therapy clinical trials 
available on the internet from “The Journal of Gene Medicine” clinical trial site 
(http://www.wiley.com/genmed/clinical), there are 1060 clinical trials (64.5%) for cancer 
treatment among the total 1644 trials updated June 2010, and most of them (23.8%) use 
adenovirus as vector. However, gene therapy goes through one of gains and losses since the 
very day of its naissance. Until late 2009, gene therapy received a series of great 
achievements after years of silence. The journal, Science, appraised 10 breakthroughs of the 
Year 2009, in which the seventh was gene therapy. It brings us a rekindled hope for 
overcoming the genetic diseases including cancer.  
Adenoviral vectors have been used extensively in cancer gene therapy (Su et al., 2008; Yang 
et al., 2007). Most of them are replication-deficient (Yang, 1995). The first generated 
replication-deficient adenovirus lacks the E1 and E3 regions. The second and third ones also 
contain E2 and/or E4 deletions (Andrews et al., 2001; Thomas et al., 2003). Because the 
replication-deficient adenoviruses can not replicate, they express the foreign therapeutic 
genes only in the cells that are initially infected. Synchronously, they also lack a specificity 
target to cancer cells (Kurihara et al., 2000). These problems may decrease the therapeutic 
effect on cancer cells and result in toxicity to normal cells. Therefore, development of a novel 
tumor-targeting adenoviral vector is needed to enhance the efficiency and specificity of 
transgene expression. Oncolytic adenoviruses are promising as therapeutic agents in cancer 
treatment. These viruses are genetically modified to target, infect and replicate in cancer 
cells causing them to lyse with an improved, superior efficacy compared to non-replicating 
adenoviral vector which lacks the E1 genes. Here, combined with the studies of our group 
(Fang et al., 2009, 2010; He et al., 2009, 2010; Hu et al., 2010; Ma et al., 2009; Su et al., 2004, 
2006a, 2006b, 2008a, 2008b), we review the development of oncolytic adenovirus-based gene 
therapy for cancer, and figured the potential prospects of gene therapy in cancer treatment. 
2. Adenovirus gene therapy 
The strategy of virotherapy, a method for the treatment of cancer with viruses, has been 
revitalized since the appearance of a series of novel conditionally replicating adenoviruses 
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(CRAds), also known as oncolytic adenoviruses (Alemany et al., 2000). These tumor-
selective replicating viruses were designed to replicate preferentially in cancer cells, but not 
in normal cells. The infection, replication and oncolytic abilities of CRAds were targeted 
specifically to cancer cells and had little or no influence on the normal cells (Kirn et al., 
2001). After infecting one cancer cell and replicating in it, the viruses replicate and lyse the 
infected cell, and the progeny virions are released and infect the rest neighboring cancer 
cells. These cycles of infections and replications carry on repeatedly, making a chain reaction 
to facilitate viral spread within the cancer tissues till all cancer cells are destroyed 
(Ramachandra et al., 2001).  
As antitumor therapeutic agents, CRAds are accordingly armed with incontestable 
advantages and is superior to replication-deficient adenovirus. There are a number of 
ongoing preclinical or clinical trials with oncolytic adenoviruses in treatment of a variety of 
cancers, such as OBP-301 (Telomelysin) in lung and prostate cancers, Ad-dl922-947, Ad-
Onyx-015, Ad-Onyx-017, Ad-vKH1 and AdEHE2F in breast, colon, head and neck cancers 
(Bazan-Peregrino et al., 2008; Ouchi et al., 2009). A product of Onyx Pharmaceuticals 
(Richmond, CA), ONYX-015, is a replicative virus studied in clinical trials for several years. 
It is a chimeric human group C adenovirus (Ad2 and Ad5) modified by deletion between 
nucleotides 2496 and 3323 in the E1B region encoding the 55-kDa protein which binds the 
tumor suppressor protein p53. ONYX-015 has an ability to selectively replicate in and kill 
many human malignant tumor cells with mutations of p53 gene (Bischoff et al., 1996; Khuri 
et al., 2000).  
Although the replicative viruses have many advantages to exert antitumor efficacy, they 
also have limitations in cancer therapy. Durable responses in clinical trials with replicative 
viruses, including ONYX-015, as single oncolytic agents have not been very encouraging 
(Ganly et al., 2000). It is not unexpected that a virus utilizing one of many mechanisms, such 
as p53 pathway, to promote its replication does not have enough power to destroy all cancer 
cells. This intrinsic limitation of targeted therapies mandates devotion to developing a series 
of selectively replicating viruses targeted to different tumorigenesis pathways, and to 
refining on replicative viruses with higher specificity, lower toxicity and stronger oncolytic 
efficacy for different tumors and different patients. 
In order that viruses will specifically infect cancer cells, and the viral replication can be 
carefully controlled for the purpose of killing cancer cells safely and effectively, a cancer-
specific expression and transportation system is required. One attempt to achieve CRAd is 
to modify adenovirus by partial deletion of viral genes (Biederer et al., 2002; Ring, 2002). The 
representative of this type of CRAd is ONYX-015. Moreover, many cancers have their own 
special markers whose expression is controlled by the particular cis-acting elements and 
trans-acting factors. Another attempt to achieve CRAd is to place viral replicative genes 
under the control of cancer-specific promoters. Although these tissue- or cancer-specific 
promoters can provide the restricted viral replication in cancer cells by controlling the 
expression of viral replicative genes, their shortcomings are obvious and cannot be ignored. 
Firstly, they are limited to a narrow range of cancers expressing the targeted tumor markers, 
and cannot be used for treatment of cancers of different origins. Secondly, most of them are 
much weaker than commonly used viral promoters such as cytomegalovirus (CMV) or SV40 
early promoter (Gu et al., 2002). The expression of the genes driven by these specific 
promoters is generally in lower levels, thus attenuating their effects in cancer therapy (Su et 
al., 2004). 
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Many attempts have been made to improve both the antitumor potency and biosafety of 
approaches combining viral oncolytic therapy and transgene therapy. Genetic re-
engineering of CRAds by incorporating therapeutic payloads may yield mutually 
supportive antitumor effects. CRAd replication selectively amplifies therapeutic transgene 
expression in cancer cells (Haviv et al., 2001; Nanda et al., 2001), and transgene expression 
synchronously increases the spread of viral progeny within a tumor cell mass (Hermiston & 
Kuhn, 2002; Van Beusechem et al., 2002). It has been shown that the approach combining 
gene therapy with oncolytic virotherapy is more effective than their use individually. Many 
therapeutic transgenes have exhibited antitumor efficacy in experimental models, including 
cytotoxic genes, suicide genes, tumor suppressor genes, apoptosis-inducing genes, 
angiogenesis-inhibiting genes and immunostimulatory genes (Haviv & Curiel, 2003; Lam & 
Breakefield, 2001). Some strategies have employed CRAds armed with immunostimulatory 
genes to enhance their overall antitumor activity. Heat shock proteins (HSPs) play 
important roles in eliciting innate and adaptive immunity by chaperoning peptides for 
antigen presentation to antigen-presenting cells and providing endogenous danger 
signalling. The recombinant oncolytic adenoviruses overexpressing the HSP70 protein can 
accordingly eradicate primary tumors, as well as inhibit the growth of established metastatic 
tumors in mice as a result of their capacity to induce individual tumor-specific immune 
responses (Huang et al., 2003). Although a few achievements have recently been made in the 
field of cancer gene therapy, great effort is still needed to select effective transgenes with 
more efficacy against cancers, and modify adenoviral vectors with more biosafety and 
specificity (Su et al., 2006a). 
2.1 Modification of adenovirus E1a gene for CRAds 
CRAds are genetically modified to express the wild type of E1a (wE1a) and showed good 
cytolytic effect in various human cancers (Hong et al., 2008; Liao et al., 2007; Su et al., 2006b, 
2008a, 2008b), which binds to cellular regulators and mediates a series of genetic events, for 
instance, suppression of transformation, tumorigenicity and cancer metastatic ability (Kim 
et al., 2007). In addition, the E1a antitumor effect may be involved in many genetic factors in 
cancer cells, including E1a-induced apoptosis (Radke et al., 2008), Ela-enhanced sensitivity 
to chemotherapeutics and radiation (Sánchez-Prieto et al., 1996), E1a-triggered accumulation 
of p53 product and the E1a-mediated down-regulation of the oncogene Neu (ErbB-2/HER2) 
expression (Bartholomeusz et al., 2005; Madhusudan et al., 2004). Neu protein is a member 
of epidermal growth factor receptor (EGFR) and is commonly overexpressed in many 
human solid cancers, eg. in breast and primary liver cancer. E1a-mediated down-regulation 
of Neu expression in cancer cells could inhibit cancer cell proliferation and progression. 
Indeed, E1a-targeted gene therapy has been tested in clinical trials in cancer patients (Yoo et 
al., 2001). Moreover, during adenovirus infection, E1a protein interacts with a number of 
cellular proteins, thereby has an important role in facilitating viral replication.  
The wE1a protein consists of three conserved regions (CR1, CR2, and CR3). These regions 
have different functions for viral antitumor effect and its replication. CR1 and CR2 are 
known to act through several cellular transcription factors, such as E2F, AP1, ATF, ETF, Sp1, 
CBP/p300, P/CAF, and USF, that interact with E1a-inducible promoters (Hale & 
Braithwaite, 1999). The N-terminus of CR1 is also required for the transcriptional activation, 
expression and stability of p53, and induces p53-dependent apoptosis (Itamochi et al., 2007). 
The CR2 domain binds to retinoblastoma tumor suppressor (Rb) protein, resulting in an 
inhibition of E2F transcription factors, and activating genes for cell cycle progression (Berk, 
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2005). The CR3 is a transcriptional activation domain that associates with CtIP, Sur2, CtBP 
(Bruton et al., 2007, 2008). However, any modification of the E1a gene which would optimise 
its antitumor efficacy without any significant negative effect on viral replication still needs 
to be investigated. 
For increasing the wE1a antitumor efficacy without decreasing its effect on viral replication, 
the 870-bp wE1a gene was modified by deleting parts of the E1a CR2 (amino acid residues 
125 to 128) and CR3 (amino acid residues 140 to 185) to yield a novel 720-bp truncated 
minimal-E1a gene (mE1a). The mE1a gene was introduced into an oncolytic adenoviral 
vector lacking the E1b genes, placing it under the control of human telomerase reverse 
transcriptase (hTERT) promoter, creating AdDC315-mE1a. The experiments showed that the 
vector was shown to give a high expression of mE1a protein in all cancer cell lines tested, 
including HepGII, A549, SGC-7901, Hela, MCF-7, HT-29, and also in HepGII xenograft 
models in nude mice where the expression was stable throughout the experiment (35 days). 
In AdDC315-mE1a treated cell lines and the xenografted tumors, the mE1a protein 
expression was selective in various cancer cell lines, but expression was negative or only 
weakly positive in the normal cells (Fang et al., 2009).  
The truncated mE1a gene was also proved to have capacities to down-regulate Neu 
expression, and also support adenoviral replication for the oncolytic vector as well as the 
wE1a gene. But there is a difference between the mE1a gene and wE1a gene, the mE1a 
gene can release Rb protein efficiently and preserve the Rb function. The Rb pathway is 
frequently defective by phosphorylation of Rb protein (pRb). When the cancer cells are 
infected with adenoviruses, the Rb protein also can be inactivated by combination with 
the E1a-CR2 domains (Nemajerova et al., 2008). Both the phosphorylation and 
combination of Rb protein resulted in the release of E2F factor, thus the E2F activity is 
high in cancer cells. The oncolytic adenovirus with a deletion of 24 bp in Rb-binding 
region of the E1a protein (amino acids 122–129) is sufficient to prevent binding to and 
inactivation of the Rb protein, but it has little effect on the functions of the E1a protein 
that are necessary for effective viral replication in cancer cells (Fueyo et al., 2000). The 
results demonstrated that the mE1a gene with a small deletion of 125-128 amino acid 
residules in Rb-binding region has a diminished binding affinity to Rb and can preserve 
Rb function.  
The adenovirus E1a can render the adenovirus-infected cells susceptible to DNA damage 
from chemotherapy and radiation. Interestingly, normal cells appear to be unaffected by E1a 
protein (Sánchez-Prieto et al., 1996). Most oncolytic adenoviruses have been engineered by 
holding E1a gene expression. Thereby, in addition to their oncolytic effects, E1a protein 
endows oncolytic adenovirus with higher antitumor potency. Since the 1990s, oncolytic 
adenoviruses with E1a expression were utilized to treat cancer patients from Phase I to 
Phase III. In 2004, China approved one kind of oncolytic adenovirus, H101, to market. 
Clinical data showed that H101 is well tolerable and has good efficacy when combined with 
chemotherapy in some cancer treatment modalities (Yu & Fang, 2007). For the purpose of 
optimizing the therapeutic efficacy of wE1a, the small truncated E1a variant, mE1A, is 
proved to be capable of down-regulating Neu expression and supporting adenovirus 
replication in the mE1a-expressed cancer cells. It has a particular strongpoint to boost Rb 
function differed from the wE1a gene. Thereby, the mE1a-supported oncolytic adenovirus is 
endowed with more effective effects on tumor growth suppression, cell cycle arrest and 
cancer cell apoptosis as demonstrated in hepatocarcinoma xenografts in nude mice (Fang et 
al., 2009). 
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2.2 Modification of tumor-selective promoters for CRAds 
Several tissue- and cell-specific promoters that are more active in the particular cancer cells, 
but inactive or only weakly active in the cancer-originating somatic cells, have been 
identified and exploited to construct CRAds or target gene transportation and expression in 
cancers, such as the carcinoembryonic antigen (CEA) promoter in colorectal and lung cancer 
(Osaki et al., 1994), the DF3/MUC1 antigen promoter in breast cancer (Kurihara et al., 2000), 
the E2F transcriptional factor promoter in cancers with a defective pRb/E2F/p16 pathway 
(Johnson et al., 2002; Ramachandra et al., 2001; Tsukuda et al., 2002), the α-fetoprotein 
promoter in hepatocellular cancer (Ohashi et al., 2001), the prostate-specific antigen (PSA) 
promoter in prostate cancer (Rodriguez et al., 1997) and the L-plastin promoter in ovarian 
and bladder cancers (Peng et al., 2001). These cancer-specific promoters can provide CRAds 
the selective replication in corresponding cancer cells and demonstrate antitumor activity in 
preclinical models and clinical trials. However, most of them limit to target a narrow range 
of cancers expressing the corresponding tumor antigen, thus attenuating their efficacy in 
cancer therapy. More efforts should be put in seek the tumor-selective promoters targeting a 
wide range of human cancers. 
2.2.1 The hTERT promoter-regulated CRAds 
A number of gene therapeutic approaches have been proposed to kill cancer cells or inhibit 
growth of caners by targeting telomerase (Hodes, 2001). Telomerase, a unique enzyme that 
synthesizes telomeric repeats, is highly activated in immortalized cell lines and most of the 
malignant tumors, but is inactive in normal somatic cells (Cong et al., 1999; Kim et al., 1994; 
Shay & Bacchetti, 1997). Telomerase activation has been regarded as a crucial step in cellular 
carcinogenesis, and it is the broadest spectrum molecular marker of malignancies found. 
More detailed analyses of telomerase activity in normal and malignant cells suggested that 
telomerase is active in most cancers, more than 85% of human primary cancers exhibit 
telomerase activity (Nowak et al., 2003; Saretzki et al., 2002), but not in normal tissues except 
hematopoietic stem cells and germ cells in the ovary and testis (Kim et al., 1994; Yui et al., 
1998). With these properties, telomerase is an ideal target for cancer gene therapy and has 
attracted an intense interest in recent years. The studies have established a possibility that 
the manipulation of telomerase function may have an important role in cancer therapeutic 
intervention. Based on the knowledge on the structure and function of telomere and 
telomerase, a number of approaches have been proposed to inhibit the growth and division 
of caner cells by targeting the telomerase (Hodes, 2001).  
Telomerase is a ribonucleoprotein complex composed of the telomerase RNA (hTR), the 
telomerase associated protein and the telomerase reverse transcriptase (hTERT). By 
cloning of the hTR and hTERT components to clarify the mechanism of telomerase 
activation, it has been demonstrated that hTR is expressed in both telomerase-positive 
and -negative cells, but hTERT is expressed only in telomerase-positive cells but not in 
telomerase-negative cells. Transferring hTERT gene into telomerase-negative cells can 
induce telomerase activation in these cells (Nakayama et al., 1998; Weinrich et al., 1997). A 
strong correlation is established between hTERT expression and telomerase activity. 
These findings strongly suggest that the hTERT component is the key determinant of 
human telomerase activity, and utilizing hTERT promoter to drive antitumoral genes in 
cancer gene therapy can target to and selectively kill the cancer cells with positive 
telomerase activity, without affecting the normal cells with negative telomerase activity 
(Koga et al., 2000; Poole et al., 2001). 
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The hTERT promoter has been cloned and identified (Cong et al., 1999; Horikawa et al., 
1999). It is highly G/C-rich and lacks TATA and CAAT boxes, and has several binding sites 
for transcriptional factors, including the transcriptional activating factors Myc (Eickbush, 
1997), SP1 (Kyo et al., 2000), and the transcriptional repressing factors Mad1 (Gunes et al., 
2000), p53 (Xu et al., 2000), MZF2 (Fujimoto et al., 2000). By measuring the transcriptional 
activity of a series of constructs containing unidirectionally deleted fragments of the hTERT 
promoter, some investigators discovered that a 181 bp fragment upstream of the 
transcriptional start site is the smallest core promoter essential for transcriptional activation 
of hTERT gene (Abdul-Ghani et al., 2000; Takakura et al., 1999). The expression of c-Myc 
oncoprotein markedly induces the transcriptional activity of the hTERT promoter in the 
endogenous hTERT-negative cells, and induces 3- to 7-fold increase of the hTERT promoter 
activity in the hTERT-positive cell lines (Horikawa et al., 1999). The mechanism of c-Myc 
protein up-regulating the hTERT promoter activity is probably through the E-box motifs 
(CACGTG) within the hTERT core promoter. It has been shown that although SP1 factor is 
over-expressed in the telomerase-negative normal somatic cells and its binding to the 
specific sites promotes the start of hTERT gene transcription, by comparison, the major 
determinant regulating the hTERT gene expression is the transcriptional factors that 
combined with E-box motifs. In addition to the E-box (-187 bp to -182 bp) upstream of the 
transcriptional start site (Horikawa et al., 1999), there is another E-box (+22 bp to +27 bp) 
downstream of the transcriptional start site (Horikawa et al., 2002). This downstream E-box 
mediates the activation or repression of hTERT gene transcription by binding c-Myc or 
Mad1 transcriptional factors, respectively (Greenberg et al., 1999; Gunes et al., 2000). The 
current research demonstrated that the downstream E-box is a target for down-regulating 
the hTERT activity in the telomerase-negative cells. But this downstream E-box changes to 
the binding site for up-regulating the hTERT gene transcription in the telomerase-positive 
cells when it combines with the transcriptional activating factors such as the upstream 
stimulatory factor (USF), a member of Myc family (Horikawa et al., 2002). Therefore, the 
expression of the hTERT gene determining the telomerase activity is firmly controlled by 
many factors including the transcriptional activating and repressing factors, and the 
regulatory sites mainly locate in the promoter region of the hTERT gene. 
Some current studies showed that the hTERT promoter which was used to construct CRAds 
by controlling the E1a gene demonstrated a sufficient activity for viral effective replication 
in cancer cells (Huang et al., 2003; Irving et al., 2004; Kawashima et al., 2004; Zou et al., 
2004). To further improve the specificity of hTERT promoter, the activity of hTERT core 
promoter could be enhanced significantly in the majority of the cancer cell lines by inserting 
the adenovirus E1a TATA box downstream of the hTERT promoter (Wirth et al., 2003). A 
CRAd, CNHK300, in which the hTERT promoter is used to replace the original regulatory 
elements of E1a gene and to control the E1a gene expression, can target to the telomerase-
positive cancer cells and replicate in them, resulting in oncolysis, when the progeny virions 
are released and infect the adjacent cancer cells, they will not affect the normal cells negative 
for telomerase activity. Another interesting approach developed an oncolytic adenovirus 
AdEHT2 in which a minimal dual-specificity promoter that responds to estrogens and 
hypoxia was used to control the viral E1a gene, and the hTERT core promoter was 
introduced into the E4 region of AdEHT2 (Hernandez-Alcoceba et al., 2002). Their 
experiments of viral replication and cytotoxicity showed that AdEHT2 was not attenuated 
in telomerase-negative cells when these cells were infected under hypoxia conditions. It was 
postulated that the good expression of the adenoviral E1a gene activated by hypoxia was 
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sufficient to promote the viral replication. They also held that the E1a protein can potentially 
stimulate the hTERT promoter in the E4 region directly or as a consequence of the cell cycle 
activation. Although the E4-deleted adenovirus was attenuated, a low level of the E4 open 
reading frame expression could support its replication under the condition that the rest 
transcriptional units of the virus were activated. Based on the published data and the 
current study, it is reasonable to conclude that the tight regulation of the adenoviral E1a 
gene is crucial for the replication of the virus.  
One of the major concerns was the potential toxicity of hTERT promoter-regulated CRAds 
to stem cells or other normal cells, although there were evidences suggesting that the toxic 
effects caused by the use of the hTERT promoter on normal cells may be transient (Chiu et 
al., 1996), and could be prevented by using the adenoviral vectors which infect stem cells 
poorly (Gu et al., 2000). The toxicity assay was performed in BALB/c mice by sequential 
intravenous injections of the hTERT promoter-regulated CRAds and the control virus (wild 
adenovirus type 5, wAd5). The main objective is to investigate whether the replicative 
adenovirus has toxicity to liver cells after systemic delivery. The results suggested that the 
hTERT promoter-regulated CRAds are less toxic than wAd5 after intravenous 
administration. They are well tolerated at a low dosage that was equal to the therapeutic 
dosage for the treatment of the transplantation tumors of nude mice. Even at a high dosage 
of hTERT promoter-regulated CRAds, mice showed no signs of toxicity in terms of 
mortality, liver enzyme levels and hepatocyte morphology, no replication of viruses was 
found in liver tissues by E1a immunohistochemistry, and only slight granular or hydropic 
degeneration of hepatocytes could be observed. Meanwhile, wAd5 displayed both a certain 
mortality and liver toxicity. All mice died at a high dosage of wAd5, and the therapeutic 
dosage induced an obvious increase of liver enzymes and evidence of cytopathic effects on 
liver tissues. Therefore, the toxic effect of hTERT promoter-regulated CRAds is much 
weakened compared with wAd5 by the use of the hTERT promoter (Su et al., 2004, 2006b, 
2008a; Wang et al., 2008).  
2.2.2 The E2F promoter-regulated CRAds 
The loose control of cell cycle is a key feature of cancer cell proliferation. Much evidence 
suggests that the Cyclin/Cyclin-dependent kinase (CDK)/P16/retinoblastoma protein 
(Rb)/E2F pathway is the major link for cell cycle control. Cyclin D1 activates CDK4 and 
promotes the phosphorylation of Rb protein, which makes the E2F transcriptional factor 
released from Rb-E2F complex. Then the E2F transcriptional factor activates the 
transcription of many important cell cycle regulatory genes, and promotes tumorigenesis. 
P16 is known as a negative regulator of cell cycle, which can block cell cycle progression 
from G1 to S phase by binding to CDK4 and inhibiting the action of Cyclin D1 (Coqueret, 
2002; Ortega et al., 2002). It was found that the inactivation of Cyclin D/ CDK/ P16/ Rb/ 
E2F pathway is a common characteristic of most solid cancers (Gemin et al., 2005; Johnson et 
al., 2002; Tsukuda et al., 2002). This pathway is an ideal target for cancer gene therapy and 
has attracted an intense interest in recent years.  
As described above, cancer cells with the deficiency of Cyclin /CDK/P16/Rb/E2F pathway 
have high activity of E2F transcriptional factor, thus this important factor is defined as a 
crucial target in cancer treatment. A CRAd, AdEHE2F, in which the expression of E4 gene is 
controlled by the E2F promoter, had been generated for breast cancer treatment (Post et al., 
2003). The tight regulation of E4 expression correlated with the viral ability to selectively 
replicate and kill cancer cells. Current study constructed an E2F promoter-regulated CRAd 
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which was armed with the p16 gene, AdE2F-p16. By controlling the E1a gene expression 
with the E2F promoter, AdE2F-p16 achieved a desired specificity to target cancer cells, while 
the normal cells were spared. The luciferase assay suggested that the E2F promoter had a 
high activity in cancer cells but not in normal cells. The data from in vitro experiments 
showed that AdE2F-p16 specifically replicated and induced E1a expression in cancer cells. 
Due to the viral replication, AdE2F-p16 more efficiently expressed P16 than the replication-
deficient adenovirus AdCMV-p16 in cancer cells. Thereby, AdE2F-p16 overcomes the 
disadvantages of low transfer rate and poor gene expression compared with the replication-
deficient adenovirus vectors. In summary, the E2F promoter-regulated, p16-armed CRAd 
can mediate the effective expression of transgene in cancer cells, and displays a satisfactory 
therapeutic effect for cancer (Ma et al., 2009). 
To further investigate the molecular mechanisms of P16-induced apoptosis, the 
consequential study found that the adenovirus-mediated P16 reactivation lead to an 
inhibition of Akt signaling pathway and a downregulation of survivin expression in 
hepatocellular carcinoma cells (Hu et al., 2010). P16 and survivin are a pair of incompatible 
factors in the cell cycle and cell apoptosis regulation. Cyclin D1 and P16 eventually regulate 
cell cycle by interacting with CDK4 (Ai et al., 2005). CDK4 and survivin are co-localized 
mainly in nuclei of the P16-deficient hepatocellular carcinoma cells. But when cancer cells 
re-express P16, the P16 protein competes with survivin for CDK4 binding and transports 
CDK4 from nuclei to cytoplasm. The translocation of CDK4 from nuclei to cytoplasm 
illuminates that its function to accelerate cell proliferation is weakened. Interestingly, it is 
found an important molecular event that the nuclear survivin is reduced obviously in cancer 
cells after P16 re-expressed. The localization of survivin in cancer cells exerts different 
functions. The nuclear survivin is involved in promoting cell proliferation, whereas the 
cytoplasmic survivin may participate in controlling cell survival (Connell et al., 2008; Li et 
al., 2005; Liu & Matsuura, 2005). Accordingly, survivin promotes cell proliferation and 
inhibits cell apoptosis by competitively interacting with CDK4, and the P16-induced 
decrease of the amount of survivin and CDK4 in nuclei contributes to the inhibition of cell 
cycle progression and induction of detachment-induced apoptosis (anoikis) in cancer cells. 
This new insight into P16 function would help in designing better strategies for cancer gene 
therapy. 
2.3 Utilization of antitumor transgenes 
CRAds can be designed to function as therapeutic gene delivery vehicles by incorporating 
antitumor transgenes, and their antitumor efficacy is thus increased by the combination of 
antitumor gene therapy and oncolytic viral therapy (Chen et al., 2005; Nagayama et al., 2003; 
Post et al., 2003; Su et al., 2006a). Previous studies confirmed the antitumor activity of 
various vectors carrying cytokine genes, such as interferons (Belardelli & Gresser, 1996), 
tumor necrosis factors (Zhang et al., 1996), drug-sensitive gene HSV-tk (Steele, 2000), 
antiangiogenesis genes (Fang et al., 2010). When these therapeutic genes were inserted into 
the genome of CRAds, they were selectively and highly expressed in cancer cells as a result 
of the cancer-selective replication of CARds, which further enhanced therapeutic effect 
targeting cancer cells without toxicity to normal tissues or cells. 
2.3.1 CRAd with interferon-gamma (IFN-γ) gene 
Interferons (IFNs) are the first cytokines to be applied clinically in treatment of human 
cancers, and have anti-proliferative effects and immune modulatory activity. They have also 
www.intechopen.com
 Adenovirus-Based Gene Therapy for Cancer 
 
137 
been shown to inhibit angiogenesis and suppress tumor vascularization (Dvorak & Gresser, 
1989; Fathallah-Shaykh et al., 2000; Singh et al., 1995). Among IFNs, IFN-γ is vital to the 
promotion of tumor surveillance in immunocompetent hosts and activates macrophages to 
nonspecifically lyse cancer cells through various mechanisms (Baratin et al., 2001; Guadagni 
et al., 1994). IFN-γ can enhance antitumor immune response by upregulating major 
histocompatibility complex class I expression and accentuating the migration of specific and 
non-specific immune cells to necrotic areas which develop spontaneously in large tumors 
(Khorana et al., 2003; Merritt et al., 2004; Peyregne et al., 2004). Gene transfer of IFN-γ 
inhibits neovascularization of tumors by inducing apoptosis of endothelial cells (Kowalczyk 
et al., 2003), suggesting that IFN-γ represses tumor growth by the dual mechanisms of 
inhibition of angiogenesis and elicitation of an immunotherapeutic response.  
In clinical trials, only high concentration of IFN-γ product in tumor tissues yields 
antiangiogenic effects and immune response. Unfortunately, high concentration of IFN-γ 
product is associated with significant toxic effects, including fever, endocrine dysfunction, 
thrombocytopenia, and hepatic toxicity (Jonasch & Haluska, 2001). Therefore, its toxicity 
limits the administration of high concentration of this agent. Based on dual antitumor 
features of the IFN-γ gene and tumor-selective replication of viruses, CRAds armed with the 
IFN-γ gene could amplify transgene copies in tumor cells and produce high local 
concentration of IFN-γ product in tumor tissues. This strategy could thus yield multiple 
antitumor effects including oncolysis, antiangiogenesis, and induction of immune response. 
Even in immunodeficient animals, delivery of IFN-γ can partially restore significant 
immune activity (Wu et al., 2001).  
In tumor models of nude mice, the IFN-γ gene-armed CRAd exhibited efficient antitumor 
activity against tumor xenografts. Many extensive foci of necrosis appeared in virus-treated 
tumor specimens. Around the necrotic foci, there were cancer cells positive for adenoviral 
capsid protein in tumor tissues, suggesting the selective replication and oncolytic effect of the 
IFN-γ gene-armed CRAd in cancer cells. The number of microvessels was clearly decreased in 
tumor tissues, which may be one of the mechanisms of IFN-γ-mediated antitumor responses 
in mice. Since suppressing tumor angiogenesis could lead to tumor starvation and regression 
(Folkman, 1998), decreasing the number of microvessels in tumor tissues might strongly 
suppress tumor growth. The present study found that more effective antitumor immune 
responses were exhibited when the IFN-γ gene-armed CRAd was used in immunocompetent 
hosts than in immunodeficient animals, because the host immune system was intact to support 
the full function of IFN-γ. After treated with the IFN-γ gene-armed CRAd, the increase in 
numbers of LCA+, CD4+, and CD8+ lymphocytes and the ratio of CD4+/CD8+ in tumor 
tissues accounted for the enhancement of immune responses to cancer cells (Su et al., 2006a). It 
is hypothesized that the combination of oncolytic virotherapy and immune gene therapy 
would enhance antitumor efficacy in both immunodeficient and immunocompetent hosts, and 
obtained results strongly supporting this hypothesis.  
2.3.2 CRAd with antiangiogenesis gene 
Increasing evidence suggests that the solid tumors and their metastasis are angiogenesis 
dependent. Angiogenesis is a complex process that includes the activation, proliferation, 
and migration of endothelial cells. This process involves in the formation of vascular tubes 
and networks. Antiangiogenic therapy attempts to stop new microvessels from forming 
around tumors and to break up the existing network of abnormal capillaries that feed the 
cancerous mass, finally mediates the inhibition of cancer growth.  
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Endostatin, a 20-kDa C-terminal fragment of collagen XVIII, is the most potent angiogenesis 
inhibitor and specifically inhibits endothelial cell proliferation and migration, induces 
apoptosis of vascular endothelial cells (Lai et al., 2007; Li et al., 2008; Ning et al., 2008), and 
has been demonstrated to be with antitumor effect in many solid tumors, and without 
toxicity, immunogenesis or resistance. The adenovirus vector carrying a secretable form of 
mouse endostatin, Av3mEndo, mediated the secreted expression of endostatin from 
Av3mEndo-transduced mammalian cells and showed a potential inhibition of endothelial 
cell migration in vitro. A single intravenous administration of Av3mEndo in mice could 
result in prolonged and elevated levels of circulating endostatin, partial inhibition of 
vascular endothelial growth factor (VEGF)-induced angiogenesis, and in 25% of mice the 
complete prevention of tumor growth (Chen et al., 2000). The CRAd, AdSu-hE, in which a 
chimeric promoter of HER2 enhancer and hTERT promoter was used to drive the E1a gene, 
a cytomegalovirus promoter to control the human endostatin gene. In vivo intratumoral 
delivery of the CRAd to pre-established hepatocellular carcinoma tumors in nude mice 
induced a significant tumor reduction and, in some cases resulted in a complete tumor 
regression (Fang et al., 2010). 
Canstatin, a novel matrix-derived inhibitor of angiogenesis, was described as being at least 
10-fold more active than endostatin (Kamphaus et al., 2000; Narazaki & Tosato, 2006). 
Experiments demonstrated that recombinant canstatin can potently inhibit endothelial cell 
proliferation, migration, and induce apoptosis in vitro. Moreover, it can successfully 
suppress the growth of implanted human xenografts of renal cell carcinoma and prostate 
tumors through antiangiogenesis effect (Kamphaus et al., 2000). The canstatin gene was 
inserted into an E1B-55kDa-deleted adenovirus vector and constructed an adenovirus, 
CRAd-Cans. It showed markedly improved inhibitory effects on the growth of the 
pancreatic cancer in mice with a prolonged survival rate through the mechanisms of 
oncolytic and anti-angiogenesis effects (He et al., 2009).  
2.3.3 CRAd with tumor suppression gene 
P16 is known as a negative regulator of cell cycle, which can block cell cycle progression 
from G1 to S phase by binding to CDK4 and inhibiting the action of Cyclin D1 (Canepa et 
al., 2007; Coqueret, 2002). It was found that the P16 inactivation is a frequent molecular 
event in most cancers. The mechanisms of P16 inactivation include the homozygous 
deletion, point mutation and 5’-CpG island methylation (Ortega et al., 2002). Due to the P16 
inactivation, cancer cells show growth superiority and high malignancy. Reactivation of P16 
by transferring the p16 gene into cancer cells induced cell G1 arrest and apoptosis (Chen et 
al., 2005), suggesting that the p16 gene may have a good future application in cancer gene 
therapy. The E2F promoter-regulated CRAd armed with the p16 gene, AdE2F-p16, was 
constructed (Ma et al., 2009). With the selective replication of AdE2F-p16 under the control 
of the E2F promoter, AdE2F-p16 expressed P16 with high levels in cancer cells. The 
improved antitumor efficacy of AdE2F-p16 was shown in human gastric cancer model in 
nude mice. The viral selective replication resulted in enhanced oncolysis, and p16 
expression induced cancer cell apoptosis, suggesting that the combined effects led to the 
tumor growth inhibition in mouse models.  
The p53 gene is one of the most important tumor suppressor gene. It plays an important role 
in cancer gene therapy, which has received preclinical validation by developing anticancer 
agents that specifically reactivate P53 function (Martins et al., 2006). To explore the efficacy 
of wild type p53 reactivation as a tumor therapy, some investigators demonstrated that 
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restoring endogenous P53 expression in mice led to regression of autochthonous 
lymphomas through cellular apoptosis pathway and sarcomas through cellular senescence 
in mice, but without affecting normal tissues (Ventura et al., 2007). By RNA interference 
(RNAi) to conditionally regulate endogenous P53 expression in a mosaic mouse model of 
liver carcinoma, it was found that even brief reactivation of endogenous P53 in p53-deficient 
tumors could produce complete tumor regressions through the induction of a cellular 
senescence that was associated with differentiation and upregulation of inflammatory 
cytokines (Xue et al., 2007). These studies indicated that the p53-triggered tumor regression 
is not only due to the cellular apoptosis but the cellular senescence program, which is 
dependent on the tumor types. The transfer of wide type p53 gene is an important method 
to cure the p53-deficient cancers (Swisher & Roth, 2002; Weill et al., 2000). A previous study 
demonstrated the enhanced antitumor effect of CRAd with the wild type p53 gene in the 
treatment of glioma (Van Beusechem et al., 2002). The tumor-specific CRAds carrying the 
wide type p53 gene, SG600-p53, can selectively replicate in tumor cells, whereas hardly 
replicated in normal cell lines, suggesting that SG600-p53 has a high selectivity to cancer 
cells and a low toxicity to normal cells. SG600-p53 expressed P53 with high efficiency in 
cancer cells. Both the high selectivity of viral replication and high efficiency of P53 
expression ensured the efficient oncolytic effect and inhibition effect on cancer cells. In NCI-
H1299 tumor xenografts in nude mice, SG600-p53 achieved the significant antitumor 
efficacy. By pathological examination, administration of SG600-p53 resulted in cancer cell 
apoptosis. It is concluded that the CRAd carrying p53 gene, as a more potent and safer 
antitumor agent, could provide a new strategy for cancer biotherapy.  
3. Problems and prospects 
The achievements of success in adenovirus-based gene therapy bring forth new hope to treat 
cancer. Many countries worldwide invested heavily in cancer gene therapy, however, there 
are few products used in clinic because of their low efficacy. The differences between the in 
vitro and in vivo experiments, basic technology and clinical application should be further 
investigated. More worrying about the long-term toxicity of transgene vector also limits the 
wide utilization of gene therapy. These problems existed and exist, but they can not 
counteract the developments and prospects of gene therapy. The traditional strategies for 
cancer treatment, including surgery, chemotherapy and radiation, are difficult to eradicate 
the root of various cancers, the gene therapy absolutely searches for the roots cause of 
carcinogenesis, and corrects the genetic defects in transformed cells. Further investigations 
on the carcinogenesis mechanism, signal transduction and genetic characteristic of cancer 
cells will promote the development and breakthrough of cancer gene therapy in the future. 
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